R&D Projects

PS100P

Signature of plasma-based cancer diagnosis and prognosis alarmins

The S100 family of calcium-binding proteins, also known as alarmins, are involved in a large number of intracellular and extracellular functions, including the control of protein phosphorylation, transcription factors in Ca2+ homeostasis, dynamics of cytoskeletal components, enzymatic activities, cell growth and differentiation, and inflammatory response. They are also considered damage-associated molecular pattern molecules (DAMPs).

There are at least 21 different types of S100 proteins, and under physiological, non-pathological conditions, most of the family members are not expressed or have very low levels, while their overexpression is found in multiple neoplastic processes, such as proliferation, survival, invasion, tumour growth, angiogenesis, and metastasis. Overexpression in neoplastic tissues involves its release into the blood, which presents us with the opportunity to study how these levels behave throughout patient treatment and/or after tumour resection.

21

types of proteins help us to predict survival in cancer patients

detailGrey

The overexpression of alarmins in the blood can help to detect and control processes such as tumour growth or metastasis.

 

The aim of the project is to develop a molecular signature of the alarmins (S100A4, S100P, S100A7, and S100A8/A9) from blood samples of breast cancer and non-small cell lung cancer (NSCLC) patients. This is in addition to the characterisation of their involvement in various cancer processes, such as tumour evasion of the immune system and resistance to immunotherapy, establishment of pre-metastatic niches, resistance to chemotherapy and biologic therapy, recurrence, etc. The correlation of the results obtained together with other parameters of each of the diseases will allow us to establish a personalised prognosis for the patient as a guide for their future treatment.

To achieve the objectives

2019-2022

In order to achieve the project’s aims, Atrys will have the collaboration of the Health & Biomedicine Unit laboratory of the technological centre Leitat, which specialises in therapy and diagnosis of oncological, inflammatory, autoimmune, and angiogenic diseases.

This project has the support of CDTI for its funding through the call for Cervera Grants for Technology Centres.

Financial blockers

Related projects